Open AccessBeyond Histology: Lowering Human Leukocyte Antigen Antibody to Improve Renal Allograft Survival in Acute Rejection
Author(s) -
Matthew J. Everly,
Lorita M. Rebellato,
Miyuki Ozawa,
Kimberly P. Briley,
Paul G. Catrou,
Carl E. Haisch,
Paul I. Terasaki
Publication year - 2010
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181cbac02
Subject(s) - medicine , thymoglobulin , antibody , plasmapheresis , panel reactive antibody , transplantation , creatinine , kidney transplantation , urology , alemtuzumab , human leukocyte antigen , gastroenterology , immunology , clinical endpoint , antigen , clinical trial
The common endpoint in the treatment of antibody-mediated rejection (AMR) is functional reversal (creatinine levels). Reduction of human leukocyte antigen (HLA) antibody strength is not commonly considered as an essential endpoint for AMR resolution. The purpose of this study was to determine whether reduction in HLA antibody intensity in patients with histologic AMR reversal influences long-term renal allograft survival.